Home / Business and Economy / Haemonetics Corp. Reports Strong Q1 FY27 Results
Haemonetics Corp. Reports Strong Q1 FY27 Results
13 Aug
Summary
- First quarter revenue reached $339 million, a 6% increase.
- Adjusted earnings per diluted share grew 4% to $1.14.
- Company raised its fiscal year 2027 guidance.
Haemonetics Corporation announced a strong start to its fiscal year 2027, with first-quarter revenue reaching $339 million, reflecting a 6% increase on both reported and organic bases. The company's adjusted earnings per diluted share also saw a 4% rise, settling at $1.14. This performance has led Haemonetics to raise its fiscal year 2027 guidance.
Management highlighted that strategic investments in enhancing its portfolio, optimizing its operating model, and strengthening commercial execution are driving this consistent profitable growth and robust cash generation. All three of Haemonetics' core platforms contributed to the quarter's success, underscoring the business's breadth and the company's potential for sustained long-term expansion.
The company also welcomed Dr. Martin Madaus to its Board of Directors. Financial reporting for the first quarter of fiscal year 2027 adheres to a newly announced reportable segment structure, with historical recast financials and explanatory materials available on the company's Investor Relations website.
